Prospects for Eradication of Meningococcal Disease

Overview

Journal Arch Dis Child

Specialty Pediatrics

Date 2012 Sep 18

PMID 22984187

Citations 12

Authors

Simon Nadel

Affiliations

Soon will be listed here.

Abstract

Meningococcal meningitis and septicaemia remain a serious global health threat. This review focuses on the epidemiology of meningococcal disease following the recent implementation of effective vaccines and the potential utility of a vaccine against serogroup B meningococcus.

Citing Articles

Invasive Meningococcal Disease in the Vaccine Era.

Nadel S, Ninis N Front Pediatr. 2018; 6:321.

PMID: 30474022 PMC: 6237846. DOI: 10.3389/fped.2018.00321.

Costs of Invasive Meningococcal Disease: A Global Systematic Review.

Wang B, Santoreneos R, Afzali H, Giles L, Marshall H Pharmacoeconomics. 2018; 36(10):1201-1222.

PMID: 29948965 DOI: 10.1007/s40273-018-0679-5.

An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate.

Fiebig T, Romano M, Oldrini D, Adamo R, Tontini M, Brogioni B NPJ Vaccines. 2017; 1:16017.

PMID: 29263856 PMC: 5707881. DOI: 10.1038/npjvaccines.2016.17.

Issues in pediatric vaccine-preventable diseases in low- to middle-income countries.

Dbaibo G, Tatochenko V, Wutzler P Hum Vaccin Immunother. 2016; 12(9):2365-77.

PMID: 27322436 PMC: 5027713. DOI: 10.1080/21645515.2016.1181243.

Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles.

Daniels-Treffandier H, de Nie K, Marsay L, Dold C, Sadarangani M, Reyes-Sandoval A PLoS One. 2016; 11(2):e0148840.

PMID: 26871712 PMC: 4752311. DOI: 10.1371/journal.pone.0148840.

References

Milagres L, Gorla M, Sacchi C, Rodrigues M . Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun. 1998; 66(10):4755-61. PMC: 108586. DOI: 10.1128/IAI.66.10.4755-4761.1998. View

Stephens D, Greenwood B, Brandtzaeg P . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007; 369(9580):2196-2210. DOI: 10.1016/S0140-6736(07)61016-2. View

Harris S, Zhu D, Murphy E, McNeil L, Wang X, Mayer L . Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Hum Vaccin. 2011; 7 Suppl:68-74. PMC: 3367671. DOI: 10.4161/hv.7.0.14564. View

Prymula R, Siegrist C, Chlibek R, Zemlickova H, Vackova M, Smetana J . Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009; 374(9698):1339-50. DOI: 10.1016/S0140-6736(09)61208-3. View

Gossger N, Snape M, Yu L, Finn A, Bona G, Esposito S . Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012; 307(6):573-82. DOI: 10.1001/jama.2012.85. View

Devoy A, Dyet K, Martin D . Stability of PorA during a meningococcal disease epidemic. J Clin Microbiol. 2005; 43(2):832-7. PMC: 548076. DOI: 10.1128/JCM.43.2.832-837.2005. View

Stephens D . Conquering the meningococcus. FEMS Microbiol Rev. 2007; 31(1):3-14. DOI: 10.1111/j.1574-6976.2006.00051.x. View

Keiser P, Biggs-Cicatelli S, Moran E, Schmiel D, Pinto V, Burden R . A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine. 2011; 29(7):1413-20. DOI: 10.1016/j.vaccine.2010.12.039. View

Holst J, Feiring B, Fuglesang J, Hoiby E, Nokleby H, Aaberge I . Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003; 21(7-8):734-7. DOI: 10.1016/s0264-410x(02)00591-1. View

10.

Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R . Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000; 181(2):761-4. DOI: 10.1086/315284. View

11.

Sierra G, Campa H, Varcacel N, Garcia I, Izquierdo P, Sotolongo P . Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991; 14(2):195-207; discussion 208-10. View

12.

Wall R, Greenwood B . Meningococcal carriage, meningococcal disease and vaccination. J Infect. 1988; 16(1):55-9. DOI: 10.1016/s0163-4453(88)96117-8. View

13.

Findlow J, Borrow R, Snape M, Dawson T, Holland A, John T . Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010; 51(10):1127-37. DOI: 10.1086/656741. View

14.

Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C . Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010; 107(45):19490-5. PMC: 2984153. DOI: 10.1073/pnas.1013758107. View

15.

Garralda M, Gledhill J, Nadel S, Neasham D, OConnor M, Shears D . Longer-term psychiatric adjustment of children and parents after meningococcal disease. Pediatr Crit Care Med. 2009; 10(6):675-80. DOI: 10.1097/PCC.0b013e3181ae785a. View

16.

Lewis L, Ngampasutadol J, Wallace R, Reid J, Vogel U, Ram S . The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010; 6(7):e1001027. PMC: 2912398. DOI: 10.1371/journal.ppat.1001027. View

17.

Masignani V, Comanducci M, Giuliani M, Bambini S, Adu-Bobie J, Arico B . Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003; 197(6):789-99. PMC: 2193853. DOI: 10.1084/jem.20021911. View

18.

Harrison L . Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010; 50 Suppl 2:S37-44. PMC: 2820831. DOI: 10.1086/648963. View

19.

Santolaya M, ORyan M, Valenzuela M, Prado V, Vergara R, Munoz A . Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012; 379(9816):617-24. DOI: 10.1016/S0140-6736(11)61713-3. View

20.

Borrow R, Joseph H, Andrews N, Acuna M, Longworth E, Martin S . Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine. 2001; 19(9-10):1129-32. DOI: 10.1016/s0264-410x(00)00317-0. View